Skip to main content

Advertisement

ADVERTISEMENT

Videos

Michail Ignatiadis, MD, PhD, Jules Bordet Institute
Videos
12/07/2023
Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.
Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.
Michail Ignatiadis, MD, PhD,...
12/07/2023
Oncology
Bradley Monk, MD
Conference Coverage
12/07/2023
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.
At the Great Debates & Updates...
12/07/2023
Oncology
Aditya Bardia, MD, MPH
Conference Coverage
12/07/2023
Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.
Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.
Aditya Bardia, MD, MPH,...
12/07/2023
Oncology

Advertisement

Antonio Llombart-Cussac MD, PhD
Conference Coverage
12/07/2023
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.
Antonio Llombart-Cussac MD, PhD,...
12/07/2023
Oncology
Hongnan Mo, MD
Conference Coverage
12/07/2023
Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.
Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.
Hongnan Mo, MD, discussed...
12/07/2023
Oncology
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
12/07/2023
Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.
Cynthia Ma, MD, leads part 2 of...
12/07/2023
Oncology

Advertisement

Sara Hurvitz, MD, Fred Hutchinson Cancer Center
Videos
12/06/2023
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results...
12/06/2023
Oncology
Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD
Videos
11/30/2023
Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...
Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...
Cynthia Ma, MD, leads part 1 of...
11/30/2023
Oncology
Gilles Salles, MD, PhD
Videos
11/27/2023
Gilles Salles, MD, PhD, highlights findings from the phase 3 SELENE trial, which aimed to assess the value of adding ibrutinib to chemotherapy among patients with previously treated follicular lymphoma or marginal zone lymphoma.
Gilles Salles, MD, PhD, highlights findings from the phase 3 SELENE trial, which aimed to assess the value of adding ibrutinib to chemotherapy among patients with previously treated follicular lymphoma or marginal zone lymphoma.
Gilles Salles, MD, PhD,...
11/27/2023
Oncology

Advertisement

Abhay Singh, MD
Videos
11/27/2023
Abhay Singh, MD, shares advice for fellow oncologists treating patients with follicular lymphoma aiming to minimize the risk of adverse events and disease transformation to AML/MDS.
Abhay Singh, MD, shares advice for fellow oncologists treating patients with follicular lymphoma aiming to minimize the risk of adverse events and disease transformation to AML/MDS.
Abhay Singh, MD, shares advice...
11/27/2023
Oncology

Advertisement